摘要
盐酸埃克替尼是一种新型的口服表皮生长因子受体酪氨酸激酶抑制剂,在体内外实验研究中显示出对非小细胞肺癌（NSCLC）的明显抑制作用.Ⅲ期临床研究ICOGEN显示埃克替尼对晚期复治NSCLC疗效与吉非替尼相当.临床用于治疗既往接受过1种或2种化疗的局部晚期或转移的NSCLC,在临床应用中,埃克替尼显示出肯定的疗效及轻微的不良反应,尤其对于表皮生长因子受体基因突变的人群更具有优势.
Icotinib hydrochloride is a novel oral epidermal growth factor receptor-tyrosine kinase inhibitor,which shows obvious inhibitory effect on non-small cell lung cancer （NSCLC） in vitro and in vivo.The phase Ⅲ clinical study （ICOGEN） shows that icotinib has a good efficacy for advanced retreatment NSCLC,compared with gefitinib.It is indicated for the treatment of patients with locally advanced or metastatic NSCLC previously treated with one or two chemotherapy regimens.In the clinical treatment,icotinib shows the positive effects and mild adverse reactions,especially for the patients who have the EGFR mutation.
出处
《国际肿瘤学杂志》
CAS
2014年第1期49-52,共4页
Journal of International Oncology
基金
浙江省自然科学基金（LY13H160024）
吴阶平医学基金会临床科研专项基金（W2012FZ134）
关键词
受体
表皮生长因子
癌
非小细胞肺
盐酸埃克替尼
蛋白酪氨酸激酶抑制剂
Receptor, epidermal growth factor
Carcinoma, non-small-cell lung
Icotinib hydrochloride
Protein-tyrosine kinase inhibitor
